Pharmacological inhibition of AKT enhances the repopulating capability of human UCB CD34+ cells. (A) Percentage of human CD45+ cells in the peripheral blood of recipient mice 4 and 8 weeks after transplantation (*p < 0.05, **p < 0.01, n = 5). (B) Frequency of human CD45+ cells in the bone marrow of recipient mice 12 weeks after transplantation (**p < 0.01, n = 4). (C) Flow cytometric analysis of human myeloid cells (CD33+/CD14+) in the bone marrow of recipient mice 12 weeks after transplantation. (D) Flow cytometric analysis of human lymphoid cells (CD3+ or CD19+) in the bone marrow of recipient mice 12 weeks after transplantation. (E) Frequency of donor-derived myeloid cells, T cells, and B cells in the bone marrow of recipient mice 12 weeks after transplantation (**p < 0.01, n = 5).